A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Recruiting
The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Primary Biliary Cholangitis, Liver Stiffness